30 unknown, 13 recruiting, 10 completed, 9 not yet recruiting. 24 Phase 2, 16 Phase 3, 11 Not applicable, 6 Phase 1, 2 Early Phase 1.
Follow Allogeneic Hematopoietic Stem Cell Transplantation: new trials by email Literature Review of Allogeneic Hematopoietic Stem Cell Transplantation trials Research Report on Allogeneic Hematopoietic Stem Cell Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Henan University of Science and Technology | 87 | 2026-11-01 | 2026-09-21 |
| Long-term Psychological and Cognitive Evaluation of Children Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Immunodeficiency Neurocognitive, psychological, and psychosocial assessement - Primary Immunodeficiencies, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-09-19 | 2026-10-16 | |
| Younger vs. Older Donors in Allo-HSCT: TTE A Target Trial Emulation Study, Donor Age | Not yet recruiting | The First Affiliated Hospital of Soochow University | 5000 | 2026-07-15 | 2026-06-24 | |
| A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation Rituximab (Arm A), Standard Post-Transplant Supportive Care - Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation | Not applicable | Not yet recruiting | Yang Donglin | 168 | 2026-07-09 | 2026-07-14 |
| Baricitinib for Post-HSCT Persistent Thrombocytopenia Baricitinib - Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 28 | 2026-03-09 | 2026-09-16 |
| Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 186 | 2026-03-01 | 2026-03-17 |
| Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT Geriatric Assessment - Elderly, Geriatric Assessment | Recruiting | Peking University People's Hospital | 176 | 2026-01-01 | 2026-09-15 | |
| Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Carbapenem-resistant Enterobacterales | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1000 | 2026-01-01 | 2026-01-07 | |
| Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cardiotoxicity, DPP3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2025-12-25 | 2026-09-25 | |
| Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation Virtual Reality Intervention - Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation | Not applicable | Not yet recruiting | Halic University | 30 | 2025-09-10 | 2025-08-28 |
| Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT) - Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 42 | 2025-09-01 | 2026-05-07 |
| Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients Liposomal Amphotericin B - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Recruiting | Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | 30 | 2025-08-01 | 2026-08-13 | |
| Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Anti-CMV immunoglobulins [Megalotect (R)] - Immunoglobulin Prophylaxis, Cytomegalovirus Infections | Recruiting | Antonello Di Paolo, M.D., Ph.D. | 150 | 2025-06-02 | 2025-06-10 | |
| Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation Maintenance Therapy with Selinexor and Azacitidine - TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | Active not recruiting | Daihong Liu | 20 | 2025-06-01 | 2025-07-30 |
| Nutrition OUtReach In Systems of Healthcare Food Bags - ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant | Not applicable | Recruiting | University of Kansas Medical Center | 210 | 2025-05-01 | 2026-04-20 |
| Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients Intervention Group, control group - Allogeneic Hematopoietic Stem Cell Transplantation | Not applicable | Enrolling by invitation | Ruijin Hospital | 180 | 2025-03-18 | 2025-04-04 |
| BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients TBICy, BuCy - T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 430 | 2024-12-01 | 2024-11-05 |
| Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus | Not yet recruiting | Ruijin Hospital | 1000 | 2024-11-01 | 2024-11-26 | |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Fludarabine, Melphalan, Total Body Irradiation - Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 60 | 2023-09-11 | 2026-02-02 |
Showing 20 of 68. Sign in to see all of them.
Leukemia, Myeloid, Acute (9) · Hematologic Neoplasms (6) · Myelodysplastic Syndromes (6) · Cytomegalovirus Infections (3) · Graft vs Host Disease (3) · Leukemia (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Bronchiolitis Obliterans Syndrome (2) · Hematologic Diseases (2) · Neoplasm, Residual (2) · Recurrence (2) · Acute Coronary Syndrome (1) · Adenoviridae Infections (1) · Arrhythmias, Cardiac (1) · Cardiotoxicity (1)
Hemic and Lymphatic Diseases (24) · Hematologic Diseases (22) · Neoplasms (20) · Neoplasms by Histologic Type (16) · Leukemia (12) · Immune System Diseases (10) · Leukemia, Myeloid (9) · Bone Marrow Diseases (6) · Infections (6) · Neoplasms by Site (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Immunoproliferative Disorders (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5)
Busulfan (10) · Decitabine (10) · Cyclophosphamide (9) · fludarabine (9) · Melphalan (5) · Sorafenib (3) · Azacitidine (2) · Blood Specimen Collection (2) · Cyclosporine (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · vedolizumab (2) · venetoclax (2) · Alemtuzumab (1) · Amphotericin B (1)
Nanfang Hospital, Southern Medical University (14) · The First Affiliated Hospital of Soochow University (6) · Assistance Publique - Hôpitaux de Paris (4) · Peking University People's Hospital (3) · Ruijin Hospital (3) · First Affiliated Hospital of Zhejiang University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · University of British Columbia (2) · Antonello Di Paolo, M.D., Ph.D. (1) · Cairo University (1) · Central Hospital, Nancy, France (1) · Centre Hospitalier Universitaire de la Réunion (1) · Daihong Liu (1)
China (42) · United States (12) · France (6) · Canada (2) · Germany (2) · Belgium (1) · Egypt (1) · Italy (1) · Norway (1) · Sweden (1) · Switzerland (1)
Qifa Liu (9) · Li Xuan, MD (3) · Depei Wu Wu, MD (2) · Agathe Escudier, MD (1) · Andrew C Harris, MD (1) · Anthony Sung, MD (1) · Bina Tejura, MD (1) · Dai-hong Liu, Dr. (1) · Depei Wu, MD (1) · Doris Ponce, MD (1) · Erlie Jiang (1)
PMID 16002928, PMID 1611601, PMID 18264142, PMID 26135532, PMID 31821456, PMID 32653622, PMID 34108672, PMID 36084276, PMID 36702138, PMID 38734654, PMID 39905816, PMID 40705849, PMID 40831735, PMID 40991367, PMID 42159161, PMID 9128987
2016 (1), R01NR021468 (1), U10HL069294 (1), U24CA076518 (1)